There is an increased risk of death for patients suffering from chronic renal failure with this drug (6%).
- TRADE NAME: Aranesp (Amgen)
- INDICATIONS: Anemia associated with renal failure and chemotherapy
- SYNONYM: erythropoiesis stimulating protein
- CLASS: Colony stimulating factor, Erythropoiesis-stimulating agent (ESA), Erythropoietin
- HALF-LIFE: 21 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of darbepoetin alfa in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 12/06/2023
